Looking forward to some feedback from the NanaBis trials later...

Looking forward to some feedback from the NanaBis trials later this quarter. Wonder when we will get some information?

The aim of this project is to conduct a safety, tolerability and exploratory end-point pilot study assessing the administration of a cannabis extract as an adjunct to opioid analgesia for the management of intractable pain in patients with a positive diagnosis of advanced cancer.

Who is it for?
You may be eligible to join this study if you are aged 18 years or over and have been diagnosed with an incurable malignancy (Stage 1 and Stage 2) and reported experiencing moderate to severe pain (Stage 2 only).

Study details
This study will be conducted in two stages. During the first stage, participants will be enrolled and remain under clinical supervision in hospital for 48 hours. On day 1, a ‘standard dose’ of 2.6 mg delta-9-tetrahydrocannabinol (THC) and 2.4 mg cannabidiol (CBD) in 0.3 mL will be administered using a buccal spray delivery system. On day 2, three ‘standard doses’ will be administered. Participants will be monitored for any adverse events during hospital stay.

Stage 2 will involve a dose escalation over 7 days commencing with one ‘standard dose’ every 4 hours and three ‘standard doses’ every 4 hours by day 7 which are then maintained until day 15. Several assessments are conducted over administration period and on day 30 post intervention commencement.

This study may greatly contribute to the research into the pharmacokinetic and medicinal properties of the Cannabis plant, in particular C. sativa L. and C. indica L. strains. The treatment may be beneficial for the treatment of intractable pain in cancer patients in conjunction with the conventional opioid treatment.​